November 17, 2016
The Japan arm of Sanofi said on November 16 that it has kicked off a post-marketing clinical study on its PCSK9 inhibitor Praluent (alirocumab), which is designed to gauge changes in intracoronary plaque levels in Japanese patients with acute coronary...read more